登录

Mei Wei Dental Raises ¥1B in Series B Funding Round 

作者: Mailman 2021-07-27 14:17
美维口腔医疗
http://www.meiweigroup.com/
企业数据由 动脉橙 提供支持
口腔医疗服务提供商 | 战略融资 | 运营中
中国-上海
2023-06-29
盛世投资
查看

(VCBeat) July. 15, 2021 -- Mei Wei Dental Group ("Mei Wei Dental"), one of China's leading dental chain brand, announced today that it has completed a Series B financing of more than 1 billion yuan, with participation from Fortune Venture Capital, TFTR Investment, New Hope Group and other well-known investors.


Before this round of financing, Mei Wei Dental has also received investments from many well-known investment institutions, including China Oriental Assets, Fortune Venture Capital, etc.


Founded in 2016, Mei Wei Dental is the first domestic oral health platform company based on the "DSO" model and created a new development model of Chinese oral industry and new format. So far, Mei Wei Dental has set up nearly 200 domestic oral clinics and hospitals, as well as a high-quality team of business partners, and has achieved positive profit in nearly two years, indicating that the "DSO" model has worked well with high recognition in the market. Mei Wei Dental has been in the leading position in the field of dental health.


As one of the oral chain companies with the highest level of digitalization, Mei Wei Dental has taken information construction as its core development strategy since its inception. Weixiaomei medical cloud intelligent management platform is built around patient-centered and medical-centered. From the improvement of the outpatient SOP process to CRM management, from the intelligent appointment system to the formulation of complete oral diagnosis and treatment plan, from the tracking of oral problems to long-term oral health management, its outpatient operation ability has been further improved efficiently. In the future, Mei Wei Dental will also integrate medical treatment, operation and management into digitalization, informatization, and intelligence.


>>>>

About Fortune Venture Capital (Fortune Capital)


Founded in April 2000, Fortune Capital is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focuses its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.


Fortune Capital is ranked among the highest-performing VC/PE firms in China. In addition to providing capital, Fortune Capital provides its investee companies with personalized value-added services.


>>>>

About TFTR Investment


TFTR Investment is dedicated to becoming the capital partner of industries and enterprises through equity investment and capital services. 

注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

迅实科技完成过亿美元D轮融资,打造一站式口腔数字化解决方案

【首发】登特菲完成数千万Pre-A轮融资,持续加大研发投入及生态扩张

【首发】云甲科技完成近亿元A轮融资,加速打造全球领先的口腔数字化整体解决方案

【首发】DeepCare羽医甘蓝完成新一轮融资,投资方为安耐德投资、松柏投资和搜狗创始人王小川

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

CellOrigin Biotech Secures ¥10 Million in a New Financing Round

2021-07-27
下一篇

Westlake Therapeutics Secures ¥100 Million in A New Round of Financing

2021-07-27